Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Gilead Sciences, Inc. < Previous 1 2 3 4 5 6 7 8 9 Next > Gilead Named Number One Overall Philanthropic Funder of HIV-Related Programs for Second Year in a Row by Funders Concerned About AIDS October 24, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD New Data Presented at EACS 2023 Further Demonstrate Strong Clinical Profile of Twice-Yearly Sunlenca® for Adults With Multi-Drug Resistant HIV October 20, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Real-World Evidence Reinforces Biktarvy® as a Long-Term Treatment Option With a High Barrier to Resistance for People With HIV and a Range of Comorbidities October 19, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program October 18, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases October 17, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers ASMB GILD Gilead and Kite Oncology Present Important New Data Across Multiple Difficult-to-Treat Cancers at ESMO Congress 2023 October 16, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Demonstrates the Impact of Global Collaboration in Advancing HIV Research and Health Equity at EACS 2023 October 16, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences to Release Third Quarter 2023 Financial Results on Tuesday, November 7, 2023 October 12, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead to Present Latest Innovative Virology Data on Current and Potentially Transformative Therapies Across HIV and COVID-19 at IDWeek 2023 October 03, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Board Director Kevin E. Lofton Named to List of Influential Leaders October 02, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Hepatic Impairment September 19, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Kite’s Car T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma September 18, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead’s Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer September 10, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Prices $2 Billion of Senior Unsecured Notes September 07, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD FDA Approves Veklury® (Remdesivir) to Treat COVID-19 in People With Mild to Severe Hepatic Impairment With no Dose Adjustment August 24, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences to Present at Upcoming Investor Conferences August 23, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Announces Partial Clinical Hold for Magrolimab Studies in AML August 21, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences and Meharry Medical College Highlight Five-Year Impact of Gilead COMPASS Initiative® on HIV in the Southern United States August 18, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead and Tentarix to Discover and Develop Novel Therapies to Address Unmet Medical Needs Across Cancer and Inflammation August 15, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences Announces Second Quarter 2023 Financial Results August 03, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD European Commission Approves Gilead’s Trodelvy® For Pre-Treated HR+/HER2- Metastatic Breast Cancer July 27, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV July 24, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD New Biktarvy® Data Presented at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic July 23, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities July 23, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS July 21, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Announces $8 Million in Grant Funding for Viral Hepatitis Relink Program in the U.S. July 20, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Showcases Latest HIV Pipeline Progress and the Impact of Global Collaboration on Health Equity Efforts at IAS 2023 July 19, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences to Release Second Quarter 2023 Financial Results on Thursday, August 3, 2023 July 14, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD FDA Approves Veklury® (Remdesivir) for COVID-19 Treatment in Patients With Severe Renal Impairment, Including Those on Dialysis July 14, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Partners with CHAI and Penta to Improve Treatment and Adherence Rates Among Children with HIV in Low and Middle Income Countries July 13, 2023 From Gilead Sciences, Inc. Via Business Wire Tickers GILD < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.